Compare Dropbox Inc (DBX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Twist Bioscience Corp — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.19B), while Twist Bioscience Corp trades at $157.03 (market cap $10.32B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is more actively traded (5,894,998 versus 2,804,312). Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Twist Bioscience Corp for 27 Days on average.
| DBX | TWST | |
|---|---|---|
Market Cap | $7.19B | $10.32B |
Volume | 2,804,312 | 5,894,998 |
Sector | Technology | Health |
52-Week High | $37.74 | $205.00 |
52-Week Low | $22.06 | $25.45 |
Typical Hold Time | 97 Days | 27 Days |
Enterprise Value | $10.05B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 1.22% on the day, with a bearish technical signal and mixed analyst ratings. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.728. Revenue remains stable around $2.5B annually, with a high gross margin of 79.72%, but net cash flow turned negative in 2025 due to significant financing outflows. Recent news highlights insider selling and a security breach affecting 5,000 accounts.
The outlook is cautious; while profitability is solid, stagnant revenue growth and high debt levels pose risks. The consensus price target of $26.83 suggests downside potential. Investor sentiment is divided, with technical indicators signaling bearish pressure. Key risks include competitive threats and execution challenges in a mature market.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
